Abstract
Lymph node status is still the single most important prognostic factor in breast cancer. Axillary surgery remains the only reliable means of providing this information. This pilot study evaluates using a highly specific radiolabelled monoclonal antibody to provide equivalent information by a non-invasive technique. After optimisation of labelling conditions, our first antibody, ICR12 (against the gene product of c-erbB-2) was evaluated in a mouse model system. Twenty-four hours post i.v. injection the mice were killed and their organs, blood and tumours harvested for counting. Tumour localisation was four times greater than that into normal tissues, reaching 20% injected dose per gram of tumour. Eight patients have had this Tc99m-ICR12. Patient selection was by immunocytochemical staining of fine needle aspirates from the patient's own breast cancer. After intravenous administration of the immunoconjugate, tomographic images were obtained at 24 h. These results were compared to the subsequent histopathological examinations. Three patients acted as normal controls, one patient was negative due to inappropriate sampling, and two patients had strong membrane staining and provided excellent tumour localisation to both breast primary and regional node metastases. A further two patients only had moderate antigen expression on staining and did not localise well. The good performance of this radiolabelled antibody with patients that strongly stain for the antigen encourages the development of this system as both a method of staging breast cancer and a potential means of immunotherapy in this subgroup of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allan, S., Dean, C., Fernando, I. et al. Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. Br J Cancer 67, 706–712 (1993). https://doi.org/10.1038/bjc.1993.130
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.130
This article is cited by
-
Multimodality imaging of the HER-kinase axis in cancer
European Journal of Nuclear Medicine and Molecular Imaging (2008)
-
Nuclear medicine techniques for the study of breast cancer
European Journal of Nuclear Medicine (1997)
-
Preclinical models for the evaluation of targeted therapies of metastatic disease
Cell Biophysics (1994)
-
Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer
Cell Biophysics (1993)